BOTHELL, Wash. — EKOS Corporation announced today that EKOS and their Netherlands
distributor, AngioCare BV, are supporting a Dutch multicentre randomized
trial (DUET) designed to compare ultrasound (US) accelerated catheter
directed thrombolysis to standard catheter directed thrombolysis in
patients with recently thrombosed infra-inguinal native arteries or
bypass grafts.
Participating Dutch investigators include: Drs. Jeal-Paul de Vries and
A.M. Schrijver (St. Antonius Hospital, Nieuwegein). Additional study
sites in the Netherlands are being added.
Robert W. Hubert, President/CEO, said, “We are pleased to support this
most important study. The hypothesis is that EKOS ultrasound accelerated
thrombolysis will significantly reduce (by at least 12 hours) therapy
time compared to standard thrombolysis alone without increasing
complication rate.”
The study is conducted in accordance with the principles of the
Declaration of Helsinki and “good clinical practice”. (The study
protocol was approved on October 13th, 2009, by the Ethics Committee of
the St. Antonius Hospital Nieuwegein. Written informed consent will be
obtained prior to randomization.
A total of 60 adult patients with recently (between 1 and 7 weeks)
thrombosed infra-inguinal native arteries or bypass grafts with acute
limb ischemia class I and IIa, (according to the Rutherford
classification for acute ischemia), will be randomly allocated to either
group A (standard thrombolysis) or group B (EKOS ultrasound accelerated
thrombolysis). The anticipated duration of recruitment will be one year.
BOTHELL, Wash. — SonoSite, Inc. (NASDAQ:SONO), the world leader and specialist in
hand-carried ultrasound for the point-of-care, today announced that its
Board of Directors has authorized SonoSite to repurchase up to $150
million of the Company’s common stock or outstanding convertible notes
for cash. In connection with the repurchase authorization, the company
will purchase up to $100 million of the Company’s common stock through a
modified “Dutch Auction” tender offer. SonoSite intends to commence the
tender offer during the week of January 18, 2010.
Under the terms of the proposed tender offer, SonoSite shareholders will
have the opportunity to tender some or all of their shares at a price
within the range of $26.10 to $30.00 per share. Based on the number of
shares tendered and the prices specified by the tendering shareholders,
SonoSite will determine the lowest per-share price within the range that
will enable it to buy $100 million in shares, or such lesser number of
shares that are properly tendered. All shares accepted for payment will
be paid the same price, regardless of whether a shareholder tendered
such shares at a lower price within the range. At the minimum price of
$26.10 per share, SonoSite would repurchase a maximum of 3,831,417
shares, which represents approximately 22% of SonoSite’s currently
outstanding common stock. SonoSite will fund the repurchase from
available cash on hand. The low and high ends of the price range
represent approximately a 0% and 15% premium, respectively, to the most
recent share closing price of $26.10 per share. Based on the January 8,
2010, closing price, the share price has increased 10% year-to-date.
The tender offer will be subject to various terms and conditions as will
be described in offer materials that will be publicly filed and
distributed to shareholders at the time of commencement of the tender
offer during the week of January 18, 2010. Additional copies of the
offer materials will also be available from the Information Agent,
Georgeson Inc. The Dealer-Manager for the tender offer will be J.P.
Morgan Securities Inc.
Kevin M. Goodwin, the Company’s President and Chief Executive Officer,
said, “After evaluating various opportunities for two years, we
concluded that the best investment of our cash was in our own stock.
Moreover, we believe that the tender offer will benefit stockholders by
providing an efficient mechanism for those who desire liquidity at a
premium over current trading prices and, for our remaining stockholders,
an enhanced ability to participate in the long-term earnings potential
of our business.”
Neither SonoSite’s management, nor any of its board of directors,
executive officers, the dealer manager, the information agent or the
depositary is making any recommendation to shareholders as to whether to
tender or refrain from tendering their shares in the proposed tender
offer. The company’s executive officers, senior management and directors
have advised the company that they do not intend to tender any of their
shares in the tender offer. Shareholders must decide how many shares
they will tender, if any, and the price within the stated range at which
they will tender their shares. Shareholders should consult their
financial and tax advisors in making this decision.
BOTHELL, Wash. — EKOS Corporation announced today that EKOS and their Netherlands
distributor, AngioCare BV, are supporting a Dutch multicentre randomized
trial (DUET) designed to compare ultrasound (US) accelerated catheter
directed thrombolysis to standard catheter directed thrombolysis in
patients with recently thrombosed infra-inguinal native arteries or
bypass grafts.
Participating Dutch investigators include: Drs. Jeal-Paul de Vries and
A.M. Schrijver (St. Antonius Hospital, Nieuwegein). Additional study
sites in the Netherlands are being added.
Robert W. Hubert, President/CEO, said, “We are pleased to support this
most important study. The hypothesis is that EKOS ultrasound accelerated
thrombolysis will significantly reduce (by at least 12 hours) therapy
time compared to standard thrombolysis alone without increasing
complication rate.”
The study is conducted in accordance with the principles of the
Declaration of Helsinki and “good clinical practice”. (The study
protocol was approved on October 13th, 2009, by the Ethics Committee of
the St. Antonius Hospital Nieuwegein. Written informed consent will be
obtained prior to randomization.
A total of 60 adult patients with recently (between 1 and 7 weeks)
thrombosed infra-inguinal native arteries or bypass grafts with acute
limb ischemia class I and IIa, (according to the Rutherford
classification for acute ischemia), will be randomly allocated to either
group A (standard thrombolysis) or group B (EKOS ultrasound accelerated
thrombolysis). The anticipated duration of recruitment will be one year.
ultrasound tech schools
|| tags: Uncategorized author: admin comments: No Comments